History


A scientific legacy spanning two decades

With the company’s founding roots in Scil Group, an offshoot of Boehringer Mannheim, Formycon’s organization and biopharmaceutical development expertise date back much farther than its name.

  • Formycon appoints development and production expert Thomas Siklosi to the Advisory Board
  • Biosimilar candidate FYB201 shows efficacy comparable to the reference product in clinical phase III
  • Formycon ranks 7th in the Financial Times list of Europe’s 1000 strongest-growing companies
  • Formycon and Aristo Pharma establish joint venture for FYB202
  • Pipeline news: FYB202 is a biosimilar candidate for Stelara®
  • Formycon changes in new SME stock exchange segment “Scale”
  • Focus magazine lists Formycon as growth champion 2017
  • German Stifterverband awards Formycon for innovative strength
  • Santo Holding (Deutschland) GmbH tranfers global commercialization rights for FYB201 to Bioeq IP AG
  • Dr. Carsten Brockmeyer again honored as one of the most influential people in medicines industry
  • Expansion of product pipeline with fourth biosimilar candidate
  • Details on FYB203: Formycon develops biosimilar for Eylea® (aflibercept)
  • Appointment of biotech expert Professor Johannes Buchner to Advisory Board
  • Enrollment of first patient in pivotal phase III study with Lucentis® biosimilar (FYB201)
  • Formycon and Bioeq initiate pivotal phase III clinical trial with Lucentis® biosimilar (FYB201)
  • Out-licensing of second biosimilar to Santo Holding
  • Medicine Maker: Dr. Carsten Brockmeyer under Top 20 in medicines industry
  • Capital increase of EUR 11.1 million
  • Successful GMP inspection
  • Development of third biosimilar begins
  • Leading East European pharmaceutical manufacturer Polpharma joins FYB201 project as a joint venture partner
  • Formycon AG appoints top US pharmaceuticals manager Bernhard Hampl to the Advisory Board
  • Successful completion of capital increase totaling EUR 17.5 million
  • Start of development of first and second product
  • Out-licensing of first biosimilar from Formycon product pipeline
  • Renaming to Formycon AG
  • Leadership in the development of high-quality biopharmaceutical follow-up-products
  • 2011: Scil Technology GmbH licenses its flagship project to Sanofi
  • 2010: Scil Technology GmbH establishes a dedicated research and services unit under the name “Formycon”
  • 2008: Scil Technology GmbH licenses project portfolio to Medtronic
  • 2003: Alongside its own R&D projects, Scil Technology GmbH wins its first service-provider contracts, conducting its first biosimilar development projects on behalf of clients
  • 2001: Analytical laboratory receives GMP certification
  • 1999: Former executives of Boehringer Mannheim found Scil Technology GmbH